Abstract #2653

Metabolic Imaging Biomarker kio Discriminates Breast Tumor Therapy Time-Courses

Wei Huang^1,2, Alina Tudorica³, Karen Y. Oh³, Stephen Y-C. Chui^2,4, Nicole Roy³, Megan L. Troxell^2,5, Arpana Naik^2,6, Kathleen A. Kemmer⁴, Yiyi Chen^2,7, Megan L. Holtorf², Aneela Afzal¹, Xin Li¹, and Charles S. Springer, Jr.¹

¹Advanced Imaging Research Center, Oregon Health & Science University, Portland, OR, United States, ²Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States, ³Diagnostic Radiology, Oregon Health & Science University, Portland, OR, United States, ⁴Medical Oncology, Oregon Health & Science University, Portland, OR, United States, ⁵Pathology, Oregon Health & Science University, Portland, OR, United States, ⁶Surgical Oncology, Oregon Health & Science University, Portland, OR, United States, ⁷Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, United States

The new DCE-MRI biomarker k_io measures on-going vital metabolic activity. For subjects with biopsy-proven breast IDC, it monitors the course of neoadjuvant therapy. While k_io decreases for most tumors, for a sub-set it increases during therapy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.